Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Verification of a Novel Multiplex PCR Respiratory Virus Panel in a US Biocontainment Unit

Identifieur interne : 000573 ( Pmc/Corpus ); précédent : 000572; suivant : 000574

Verification of a Novel Multiplex PCR Respiratory Virus Panel in a US Biocontainment Unit

Auteurs : Christina L. Dean ; Emily Alvey ; Crystal Evans ; Charles Hill ; Eileen Burd ; Colleen Kraft

Source :

RBID : PMC:7109885

Abstract

Abstract

Emerging infectious diseases carry unique logistical, financial, and clinical ramifications. Rapid diagnostic testing methods can alleviate some of these challenges by providing definitive diagnoses earlier in the clinical course, leading to appropriate targeted therapy, cost savings, and improved patient outcomes. The BioFire FilmArray Respiratory Panel 2 plus (RP2plus; bioMérieux, Marcy l’Etoile, France) is a multiplexed nucleic acid test for detection of Middle East respiratory syndrome coronavirus (MERS-CoV) and 14 common viral and 4 bacterial respiratory pathogens in nasopharyngeal swabs obtained from those meeting MERS-CoV epidemiological criteria. The aim of this study was to verify the FilmArray RP2plus for use in our biocontainment unit. Of note, the RP2plus is FDA approved but not currently available for sale in the United States. Eight patient samples were tested with known results (GenMark Respiratory Virus Panel [RVP] or Cepheid Xpert Flu/RSV). We had concordant results between the platforms for samples containing influenza A, respiratory syncytial virus (RSV), parainfluenza virus 2, rhinovirus, and a negative sample. We evaluated two influenza B samples from two different patients. The FilmArray RP2plus did not detect influenza B in one of the patient samples. The sample was exhausted and repeat testing could not be performed. A second rhinovirus sample was not detected by the RP2plus, but Coronavirus 229E was detected in this sample, a virus not detected by the RVP. The sample was repeated and again did not detect rhinovirus. Further investigation into this discrepancy revealed that rhinovirus was originally detected by RVP at a signal of 34.4 nA (repeat of 46.9 nA). The concordant rhinovirus sample had a signal of 226.7 nA by RVP, which was much higher than the discrepant sample. Because of the low signal by RVP in the discrepant sample, perhaps the viral load was below the limit of detection of the RP2plus. All other quality control sample pools passed verification testing, including day-to-day and operator variance. It is not uncommon for a person under investigation (PUI) for a highly communicable disease to be evaluated in our facility. The performance of the RP2plus test on clinical samples showed acceptable concordance with our current means of testing for respiratory pathogens. The RP2plus will eliminate challenges implicated in storing and transporting specimens to an off-site lab, facilitate quicker turnaround time, and streamline the often cumbersome, complex protocols and practices required to work up a serious communicable disease.


Url:
DOI: 10.1093/ajcp/aqz112.013
PubMed: NONE
PubMed Central: 7109885

Links to Exploration step

PMC:7109885

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Verification of a Novel Multiplex PCR Respiratory Virus Panel in a US Biocontainment Unit</title>
<author>
<name sortKey="Dean, Christina L" sort="Dean, Christina L" uniqKey="Dean C" first="Christina L" last="Dean">Christina L. Dean</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Alvey, Emily" sort="Alvey, Emily" uniqKey="Alvey E" first="Emily" last="Alvey">Emily Alvey</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Evans, Crystal" sort="Evans, Crystal" uniqKey="Evans C" first="Crystal" last="Evans">Crystal Evans</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Hill, Charles" sort="Hill, Charles" uniqKey="Hill C" first="Charles" last="Hill">Charles Hill</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Burd, Eileen" sort="Burd, Eileen" uniqKey="Burd E" first="Eileen" last="Burd">Eileen Burd</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kraft, Colleen" sort="Kraft, Colleen" uniqKey="Kraft C" first="Colleen" last="Kraft">Colleen Kraft</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmc">7109885</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109885</idno>
<idno type="RBID">PMC:7109885</idno>
<idno type="doi">10.1093/ajcp/aqz112.013</idno>
<idno type="pmid">NONE</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000573</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000573</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Verification of a Novel Multiplex PCR Respiratory Virus Panel in a US Biocontainment Unit</title>
<author>
<name sortKey="Dean, Christina L" sort="Dean, Christina L" uniqKey="Dean C" first="Christina L" last="Dean">Christina L. Dean</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Alvey, Emily" sort="Alvey, Emily" uniqKey="Alvey E" first="Emily" last="Alvey">Emily Alvey</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Evans, Crystal" sort="Evans, Crystal" uniqKey="Evans C" first="Crystal" last="Evans">Crystal Evans</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Hill, Charles" sort="Hill, Charles" uniqKey="Hill C" first="Charles" last="Hill">Charles Hill</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Burd, Eileen" sort="Burd, Eileen" uniqKey="Burd E" first="Eileen" last="Burd">Eileen Burd</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kraft, Colleen" sort="Kraft, Colleen" uniqKey="Kraft C" first="Colleen" last="Kraft">Colleen Kraft</name>
<affiliation>
<nlm:aff id="AF0001"></nlm:aff>
</affiliation>
</author>
</analytic>
<series>
<title level="j">American Journal of Clinical Pathology</title>
<idno type="ISSN">0002-9173</idno>
<idno type="eISSN">1943-7722</idno>
<imprint>
<date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<title>Abstract</title>
<p>Emerging infectious diseases carry unique logistical, financial, and clinical ramifications. Rapid diagnostic testing methods can alleviate some of these challenges by providing definitive diagnoses earlier in the clinical course, leading to appropriate targeted therapy, cost savings, and improved patient outcomes. The BioFire FilmArray Respiratory Panel 2
<italic>plus</italic>
(RP2
<italic>plus</italic>
; bioMérieux, Marcy l’Etoile, France) is a multiplexed nucleic acid test for detection of Middle East respiratory syndrome coronavirus (MERS-CoV) and 14 common viral and 4 bacterial respiratory pathogens in nasopharyngeal swabs obtained from those meeting MERS-CoV epidemiological criteria. The aim of this study was to verify the FilmArray RP2
<italic>plus</italic>
for use in our biocontainment unit. Of note, the RP2
<italic>plus</italic>
is FDA approved but not currently available for sale in the United States. Eight patient samples were tested with known results (GenMark Respiratory Virus Panel [RVP] or Cepheid Xpert Flu/RSV). We had concordant results between the platforms for samples containing influenza A, respiratory syncytial virus (RSV), parainfluenza virus 2, rhinovirus, and a negative sample. We evaluated two influenza B samples from two different patients. The FilmArray RP2
<italic>plus</italic>
did not detect influenza B in one of the patient samples. The sample was exhausted and repeat testing could not be performed. A second rhinovirus sample was not detected by the RP2
<italic>plus</italic>
, but Coronavirus 229E was detected in this sample, a virus not detected by the RVP. The sample was repeated and again did not detect rhinovirus. Further investigation into this discrepancy revealed that rhinovirus was originally detected by RVP at a signal of 34.4 nA (repeat of 46.9 nA). The concordant rhinovirus sample had a signal of 226.7 nA by RVP, which was much higher than the discrepant sample. Because of the low signal by RVP in the discrepant sample, perhaps the viral load was below the limit of detection of the RP2
<italic>plus</italic>
. All other quality control sample pools passed verification testing, including day-to-day and operator variance. It is not uncommon for a person under investigation (PUI) for a highly communicable disease to be evaluated in our facility. The performance of the RP2
<italic>plus</italic>
test on clinical samples showed acceptable concordance with our current means of testing for respiratory pathogens. The RP2
<italic>plus</italic>
will eliminate challenges implicated in storing and transporting specimens to an off-site lab, facilitate quicker turnaround time, and streamline the often cumbersome, complex protocols and practices required to work up a serious communicable disease.</p>
</div>
</front>
</TEI>
<pmc article-type="abstract">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Am J Clin Pathol</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Clin. Pathol</journal-id>
<journal-id journal-id-type="publisher-id">ajcp</journal-id>
<journal-title-group>
<journal-title>American Journal of Clinical Pathology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0002-9173</issn>
<issn pub-type="epub">1943-7722</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
<publisher-loc>US</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmc">7109885</article-id>
<article-id pub-id-type="doi">10.1093/ajcp/aqz112.013</article-id>
<article-id pub-id-type="publisher-id">aqz112.013</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>2019 ACLPS Annual Meeting Abstracts</subject>
<subj-group subj-group-type="category-toc-heading">
<subject>ACLPS Abstracts</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Verification of a Novel Multiplex PCR Respiratory Virus Panel in a US Biocontainment Unit</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dean</surname>
<given-names>Christina L</given-names>
</name>
<xref ref-type="aff" rid="AF0001"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alvey</surname>
<given-names>Emily</given-names>
</name>
<xref ref-type="aff" rid="AF0001"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Evans</surname>
<given-names>Crystal</given-names>
</name>
<xref ref-type="aff" rid="AF0001"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hill</surname>
<given-names>Charles</given-names>
</name>
<xref ref-type="aff" rid="AF0001"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burd</surname>
<given-names>Eileen</given-names>
</name>
<xref ref-type="aff" rid="AF0001"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kraft</surname>
<given-names>Colleen</given-names>
</name>
<xref ref-type="aff" rid="AF0001"></xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<institution>Emory University School of Medicine</institution>
</aff>
<pub-date pub-type="ppub">
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub" iso-8601-date="2019-09-11">
<day>11</day>
<month>9</month>
<year>2019</year>
</pub-date>
<volume>152</volume>
<issue>Suppl 1</issue>
<issue-title>2019 ASCP and ACLPS Annual Meeting Abstracts</issue-title>
<fpage>S7</fpage>
<lpage>S7</lpage>
<permissions>
<copyright-statement>© American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="publisher-standard" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model">
<license-p>This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
<ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model">https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model</ext-link>
)</license-p>
</license>
<license>
<license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p>
</license>
</permissions>
<self-uri xlink:href="aqz112.013.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>Emerging infectious diseases carry unique logistical, financial, and clinical ramifications. Rapid diagnostic testing methods can alleviate some of these challenges by providing definitive diagnoses earlier in the clinical course, leading to appropriate targeted therapy, cost savings, and improved patient outcomes. The BioFire FilmArray Respiratory Panel 2
<italic>plus</italic>
(RP2
<italic>plus</italic>
; bioMérieux, Marcy l’Etoile, France) is a multiplexed nucleic acid test for detection of Middle East respiratory syndrome coronavirus (MERS-CoV) and 14 common viral and 4 bacterial respiratory pathogens in nasopharyngeal swabs obtained from those meeting MERS-CoV epidemiological criteria. The aim of this study was to verify the FilmArray RP2
<italic>plus</italic>
for use in our biocontainment unit. Of note, the RP2
<italic>plus</italic>
is FDA approved but not currently available for sale in the United States. Eight patient samples were tested with known results (GenMark Respiratory Virus Panel [RVP] or Cepheid Xpert Flu/RSV). We had concordant results between the platforms for samples containing influenza A, respiratory syncytial virus (RSV), parainfluenza virus 2, rhinovirus, and a negative sample. We evaluated two influenza B samples from two different patients. The FilmArray RP2
<italic>plus</italic>
did not detect influenza B in one of the patient samples. The sample was exhausted and repeat testing could not be performed. A second rhinovirus sample was not detected by the RP2
<italic>plus</italic>
, but Coronavirus 229E was detected in this sample, a virus not detected by the RVP. The sample was repeated and again did not detect rhinovirus. Further investigation into this discrepancy revealed that rhinovirus was originally detected by RVP at a signal of 34.4 nA (repeat of 46.9 nA). The concordant rhinovirus sample had a signal of 226.7 nA by RVP, which was much higher than the discrepant sample. Because of the low signal by RVP in the discrepant sample, perhaps the viral load was below the limit of detection of the RP2
<italic>plus</italic>
. All other quality control sample pools passed verification testing, including day-to-day and operator variance. It is not uncommon for a person under investigation (PUI) for a highly communicable disease to be evaluated in our facility. The performance of the RP2
<italic>plus</italic>
test on clinical samples showed acceptable concordance with our current means of testing for respiratory pathogens. The RP2
<italic>plus</italic>
will eliminate challenges implicated in storing and transporting specimens to an off-site lab, facilitate quicker turnaround time, and streamline the often cumbersome, complex protocols and practices required to work up a serious communicable disease.</p>
</abstract>
<counts>
<page-count count="1"></page-count>
</counts>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000573 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000573 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:7109885
   |texte=   Verification of a Novel Multiplex PCR Respiratory Virus Panel in a US Biocontainment Unit
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:NONE" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021